← Oncology Approval Tracker

FDA DECISION ·

Releuko

filgrastim-ayow · Kashiv BioSciences

Biosimilar approvalBiosimilarCancer-related neutropenia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Filgrastim biosimilar for labeled oncology supportive uses including febrile-neutropenia risk reduction during myelosuppressive chemotherapy, recovery after AML chemotherapy, and neutropenia support after myeloablative therapy followed by bone marrow transplantation.

LAMPGEN ANALYSIS

Why it matters

The biosimilar expands availability of short-acting growth-factor products for established labeled settings.

What research teams should watch

Specify the product and track doses relative to the chemotherapy or transplant schedule.

PRIMARY RECORDS

Sources